For Sale: Two Auditing Businesses; Price: Successful IMS-SDI Merger
This article was originally published in The Pink Sheet Daily
The Federal Trade Commission requires IMS to sell SDI's promotional and medical audits businesses to an as yet to be named buyer.
You may also be interested in...
The court affirms the Second Circuit's ruling that a Vermont statute prohibiting drug companies from using Rx data to market to doctors imposes an impermissible restriction on free speech.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.